PURPOSE: TIMP-3 (tissue inhibitor of metalloproteinases-3) is 1 of 4 members of a family of proteins that were originally classified according to their ability to inhibit matrix metalloproteinases. We analyzed TIMP-3 methylation in 175 urine sediment DNA samples from patients with bladder cancer with well characterized clinicopathological parameters, including patient outcome. MATERIALS AND METHODS: We examined urine sediment DNA for aberrant methylation of 9 genes, including TIMP-3, by quantitative fluorogenic real-time polymerase chain reaction. RESULTS: Using an optimal cutoff value by TaqMan(R) quantitation we found that the risk of death was statistically significantly higher in patients with higher TIMP-3 and ARF methylation (HR 1.99, 95% CI 1.12 to 3.27, p = 0.01 and HR 1.66, 95% CI 1.00 to 2.76, p = 0.05, respectively) than in patients without/lower TIMP3 and ARF methylation in urine. A significant correlation was also seen between the risk of death and stage 3 tumor (HR 2.73, 95% CI 1.58 to 4.72, p = 0.003) and metastasis (HR 3.32, 95% CI 1.98 to 5.57, p = 0.0001). Multivariate analysis subsequently revealed that TIMP-3 methylation was an independent prognostic factor for bladder cancer survival with stage and metastasis (p = 0.001 and 0.02, respectively). CONCLUSIONS: These results suggest that TIMP-3 promoter methylation could be a clinically applicable marker for bladder cancer progression.
PURPOSE:TIMP-3 (tissue inhibitor of metalloproteinases-3) is 1 of 4 members of a family of proteins that were originally classified according to their ability to inhibit matrix metalloproteinases. We analyzed TIMP-3 methylation in 175 urine sediment DNA samples from patients with bladder cancer with well characterized clinicopathological parameters, including patient outcome. MATERIALS AND METHODS: We examined urine sediment DNA for aberrant methylation of 9 genes, including TIMP-3, by quantitative fluorogenic real-time polymerase chain reaction. RESULTS: Using an optimal cutoff value by TaqMan(R) quantitation we found that the risk of death was statistically significantly higher in patients with higher TIMP-3 and ARF methylation (HR 1.99, 95% CI 1.12 to 3.27, p = 0.01 and HR 1.66, 95% CI 1.00 to 2.76, p = 0.05, respectively) than in patients without/lower TIMP3 and ARF methylation in urine. A significant correlation was also seen between the risk of death and stage 3 tumor (HR 2.73, 95% CI 1.58 to 4.72, p = 0.003) and metastasis (HR 3.32, 95% CI 1.98 to 5.57, p = 0.0001). Multivariate analysis subsequently revealed that TIMP-3 methylation was an independent prognostic factor for bladder cancer survival with stage and metastasis (p = 0.001 and 0.02, respectively). CONCLUSIONS: These results suggest that TIMP-3 promoter methylation could be a clinically applicable marker for bladder cancer progression.
Authors: J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: Susan V Harden; Yutaka Tokumaru; William H Westra; Steven Goodman; Steven A Ahrendt; Stephen C Yang; David Sidransky Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: K E Bachman; J G Herman; P G Corn; A Merlo; J F Costello; W K Cavenee; S B Baylin; J R Graff Journal: Cancer Res Date: 1999-02-15 Impact factor: 12.701
Authors: J P Stein; G D Grossfeld; D A Ginsberg; D Esrig; J A Freeman; A J Figueroa; D G Skinner; R J Cote Journal: J Urol Date: 1998-09 Impact factor: 7.450
Authors: Malcolm V Brock; Mingzhou Gou; Yoshimitsu Akiyama; Alison Muller; Tsung-Teh Wu; Elizabeth Montgomery; Mari Deasel; Paul Germonpré; Lewis Rubinson; Richard F Heitmiller; Stephen C Yang; Arlene A Forastiere; Stephen B Baylin; James G Herman Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: Mohammad Obaidul Hoque; Chyi-Chia R Lee; Paul Cairns; Mark Schoenberg; David Sidransky Journal: Cancer Res Date: 2003-05-01 Impact factor: 12.701
Authors: Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey Journal: Cancer Res Date: 2012-04-16 Impact factor: 12.701
Authors: Megan L Durr; Wojciech K Mydlarz; Chunbo Shao; Marianna L Zahurak; Alice Y Chuang; Mohammad O Hoque; William H Westra; Nanette J Liegeois; Joseph A Califano; David Sidransky; Patrick K Ha Journal: PLoS One Date: 2010-05-26 Impact factor: 3.240
Authors: Rodrigo García-Baquero; Patricia Puerta; Manuel Beltran; Miguel Alvarez-Mújica; Jose Luis Alvarez-Ossorio; Marta Sánchez-Carbayo Journal: Tumour Biol Date: 2014-02-28
Authors: Mariana Brait; Shahnaz Begum; André L Carvalho; Santanu Dasgupta; André L Vettore; Bogdan Czerniak; Otávia L Caballero; William H Westra; David Sidransky; Mohammad Obaidul Hoque Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254